Index RUT P/E - EPS (ttm) -2.25 Insider Own 45.74% Shs Outstand 48.08M Perf Week 3.33%
Market Cap 2.17B Forward P/E - EPS next Y -3.14 Insider Trans -1.12% Shs Float 26.11M Perf Month 11.54%
Enterprise Value 1.81B PEG - EPS next Q -0.71 Inst Own 43.78% Short Float 9.88% Perf Quarter 48.76%
Income -101.46M P/S - EPS this Y -350.27% Inst Trans 13.17% Short Ratio 5.70 Perf Half Y 238.06%
Sales 0.00M P/B 5.71 EPS next Y -0.33% ROA -28.15% Short Interest 2.58M Perf YTD 8.69%
Book/sh 7.89 P/C 5.64 EPS next 5Y - ROE -36.13% 52W High 49.25 -8.57% Perf Year 250.97%
Cash/sh 7.98 P/FCF - EPS past 3/5Y - - ROIC -25.44% 52W Low 6.71 571.09% Perf 3Y -
Dividend Est. - EV/EBITDA - Sales past 3/5Y - - Gross Margin - Volatility 9.31% 7.47% Perf 5Y -
Dividend TTM - EV/Sales - EPS Y/Y TTM - Oper. Margin - ATR (14) 3.11 Perf 10Y -
Dividend Ex-Date - Quick Ratio 17.70 Sales Y/Y TTM - Profit Margin - RSI (14) 54.42 Recom 1.00
Dividend Gr. 3/5Y - - Current Ratio 17.70 EPS Q/Q -1029.60% SMA20 2.86% Beta 4.42 Target Price 51.12
Payout - Debt/Eq 0.06 Sales Q/Q -100.00% SMA50 8.49% Rel Volume 1.47 Prev Close 43.95
Employees 125 LT Debt/Eq 0.05 Earnings Nov 06 AMC SMA200 85.08% Avg Volume 452.63K Price 45.03
IPO Jan 31, 2025 Option/Short Yes / Yes EPS/Sales Surpr. 6.81% -Trades
Volume 663,464 Change 2.46%
Date
Action
Analyst
Rating Change
Price Target Change
Dec-04-25 Initiated Wells Fargo
Overweight
$55
Nov-14-25 Initiated Raymond James
Outperform
Sep-02-25 Initiated BTIG Research
Buy
$30
Jul-23-25 Initiated H.C. Wainwright
Buy
$34
Jul-08-25 Initiated Wedbush
Outperform
$17
Feb-04-26 07:00AM
Jan-05-26 07:00AM
Nov-06-25 04:01PM
07:00AM
Nov-04-25 07:00AM
04:43PM
Loading…
Oct-28-25 04:43PM
Oct-06-25 07:00AM
Sep-19-25 04:02PM
Sep-17-25 06:22PM
Sep-12-25 07:45AM
(Clinical Trials Arena) -6.07%
06:45AM
Sep-11-25 09:29AM
(Investor's Business Daily) +54.81%
07:35AM
07:30AM
Sep-02-25 07:00AM
04:01PM
Loading…
Aug-12-25 04:01PM
Jul-31-25 07:46AM
Jul-10-25 04:05PM
May-29-25 07:30AM
May-14-25 04:01PM
May-13-25 07:30AM
Mar-31-25 07:30AM
Mar-26-25 05:02PM
Feb-25-25 04:11PM
Feb-10-25 07:09AM
Feb-07-25 08:00AM
Jan-30-25 08:13PM
07:30PM
02:57PM
Maze Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular, and related metabolic, or CVRM diseases. Its pipeline includes the Compass platform, which allows it to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process to refer a variant functionalization. The company was founded by Mark Daly, Aaron D. Gitler, Stephen Elledge, Sekar Kathiresan, and Jonathan S. Weissman on August 29, 2017 and is headquartered in San Francisco, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Bernstein Harold President, R&D & CMO Feb 02 '26 Option Exercise 10.42 15,000 156,300 15,000 Feb 04 04:25 PM Bernstein Harold President, R&D & CMO Feb 02 '26 Sale 46.02 15,000 690,334 0 Feb 04 04:25 PM Bachrodt Amy SVP, Finance Feb 02 '26 Option Exercise 10.42 5,000 52,100 17,965 Feb 04 04:23 PM Bachrodt Amy SVP, Finance Feb 02 '26 Sale 46.04 5,000 230,219 12,965 Feb 04 04:23 PM Dandekar Atul CSBO Jan 29 '26 Option Exercise 10.42 7,500 78,150 18,003 Feb 02 04:21 PM Dandekar Atul CSBO Jan 29 '26 Sale 44.27 7,500 331,990 10,503 Feb 02 04:21 PM Bachrodt Amy SVP, Finance Jan 22 '26 Option Exercise 10.42 5,000 52,100 17,965 Jan 26 04:10 PM Bachrodt Amy SVP, Finance Jan 22 '26 Sale 45.52 5,000 227,612 12,965 Jan 26 04:10 PM SEKAR KATHIRESAN Former Director Jan 16 '26 Proposed Sale 40.67 29,772 1,210,937 Jan 16 04:28 PM Bernstein Harold President, R&D & CMO Jan 07 '26 Option Exercise 10.42 25,156 262,126 25,156 Jan 09 04:51 PM Bernstein Harold President, R&D & CMO Jan 07 '26 Sale 40.20 25,156 1,011,299 0 Jan 09 04:51 PM Sohn Catherine A. Director Jan 07 '26 Option Exercise 10.42 26,920 280,506 26,920 Jan 08 04:30 PM Sohn Catherine A. Director Jan 06 '26 Option Exercise 10.42 2,493 25,977 2,493 Jan 08 04:30 PM Sohn Catherine A. Director Jan 07 '26 Sale 39.11 26,920 1,052,785 0 Jan 08 04:30 PM Sohn Catherine A. Director Jan 06 '26 Sale 38.62 2,493 96,270 0 Jan 08 04:30 PM CATHERINE SOHN Director Jan 07 '26 Proposed Sale 39.11 26,920 1,052,785 Jan 07 04:00 PM CATHERINE SOHN Director Jan 06 '26 Proposed Sale 38.62 2,493 96,270 Jan 06 04:36 PM Bernstein Harold President, R&D & CMO Jan 02 '26 Option Exercise 10.42 4,432 46,181 4,432 Jan 06 04:31 PM Bernstein Harold President, R&D & CMO Jan 05 '26 Option Exercise 10.42 412 4,293 412 Jan 06 04:31 PM Bernstein Harold President, R&D & CMO Jan 02 '26 Sale 40.43 4,432 179,188 0 Jan 06 04:31 PM Bernstein Harold President, R&D & CMO Jan 05 '26 Sale 40.00 412 16,480 0 Jan 06 04:31 PM Bachrodt Amy SVP, Finance Jan 02 '26 Option Exercise 10.42 5,000 52,100 17,965 Jan 06 04:30 PM Bachrodt Amy SVP, Finance Jan 02 '26 Sale 39.15 5,000 195,754 12,965 Jan 06 04:30 PM Dandekar Atul CSBO Dec 29 '25 Option Exercise 10.42 72,400 754,408 82,903 Dec 31 04:24 PM Dandekar Atul CSBO Dec 30 '25 Option Exercise 10.42 100 1,042 10,603 Dec 31 04:24 PM Dandekar Atul CSBO Dec 29 '25 Sale 40.56 72,400 2,936,763 10,503 Dec 31 04:24 PM Dandekar Atul CSBO Dec 30 '25 Sale 40.36 100 4,036 10,503 Dec 31 04:24 PM Bernstein Harold President, R&D & CMO Dec 29 '25 Option Exercise 10.42 45,000 468,900 45,000 Dec 31 04:22 PM Bernstein Harold President, R&D & CMO Dec 29 '25 Sale 40.56 45,000 1,825,355 0 Dec 31 04:22 PM Bachrodt Amy SVP, Finance Dec 29 '25 Option Exercise 10.42 10,000 104,200 22,965 Dec 31 04:20 PM Bachrodt Amy SVP, Finance Dec 30 '25 Option Exercise 10.42 5,000 52,100 17,965 Dec 31 04:20 PM Bachrodt Amy SVP, Finance Dec 29 '25 Sale 40.58 10,000 405,766 12,965 Dec 31 04:20 PM Bachrodt Amy SVP, Finance Dec 30 '25 Sale 40.08 5,000 200,407 12,965 Dec 31 04:20 PM HAROLD BERNSTEIN Officer Dec 29 '25 Proposed Sale 42.10 105,000 4,420,500 Dec 29 04:28 PM ATUL P DANDEKAR Officer Dec 29 '25 Proposed Sale 42.10 87,500 3,683,750 Dec 29 04:25 PM SEKAR KATHIRESAN Former Board Member Dec 04 '25 Proposed Sale 42.54 10,000 425,423 Dec 04 04:08 PM SEKAR KATHIRESAN Former Board Member Nov 21 '25 Proposed Sale 35.80 27,500 984,588 Nov 21 04:09 PM SCHELLER RICHARD H Director Sep 15 '25 Sale 22.37 20,744 464,035 0 Sep 16 04:26 PM RICHARD SCHELLER Director Sep 15 '25 Proposed Sale 22.37 20,744 464,035 Sep 15 04:07 PM
